Beksaroten etkileşimleri

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (Asitretin etiketi, Kontrendikasyonlar)

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (Beksaroten etiketi, Uyarılar ve önlemler)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minosiklin etiketi, Uyarılar ve önlemler)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (Tetrasiklin etiketi, Uyarılar)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin etiketi, Kontrendikasyonlar)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (Beksaroten etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (İvakaftor etiketi, Uyarılar ve önlemler)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (Metotreksat etiketi, İlaç etkileşimleri)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat etiketi, İlaç etkileşimleri)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Monitor and replace thyroid hormone if needed. (Beksaroten etiketi, Uyarılar ve önlemler)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Beksaroten etiketi, Uyarılar ve önlemler)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (Beksaroten etiketi, Uyarılar ve önlemler)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (Beksaroten etiketi, Uyarılar ve önlemler)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (Flukonazol etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (Beksaroten etiketi, İlaç etkileşimleri)